Glucose Tracking for Children Is Moving Into Apps and Smart Devices
A significant shift is underway in pediatric health monitoring. Dexcom's Stelo, the first over-the-counter (OTC) continuous glucose monitor (CGM) cleared by the U.S. Food and Drug Administration for use in children, is pushing glucose tracking out of the clinical setting and into the everyday world of apps and wearable smart devices. For parents, school nurses, health care providers, and employee benefits managers, this development raises important questions about access, oversight, and coverage — questions that deserve thoughtful answers as the technology becomes more widely adopted.
What Is the Dexcom Stelo and Why Does the FDA Clearance Matter?
The Dexcom Stelo is a small, wearable biosensor that continuously measures glucose levels beneath the skin and transmits that data to a connected smartphone app in real time. Until recently, CGM devices required a prescription and were primarily associated with managing diagnosed conditions such as Type 1 or Type 2 diabetes. The FDA's decision to clear the Stelo for over-the-counter use — and now to extend that clearance to children — fundamentally changes who can access this kind of health data and how easily they can get it.
This is not a minor regulatory footnote. It marks the first time that continuous, real-time glucose data has been made broadly available to pediatric users without a formal prescription or a physician-managed device initiation process. For families who have long relied on finger-stick blood glucose tests or who have struggled to access CGM technology through insurance, the OTC clearance represents a genuine leap forward in accessibility.
The Stelo connects to a dedicated smartphone app that presents glucose readings in an easy-to-understand format, including trend arrows and alerts when levels move outside of set ranges. This makes the data usable not just for clinicians, but for parents, caregivers, and even older children who can learn to interpret and act on their own glucose patterns.
How App-Based Glucose Monitoring Changes Pediatric Health Management
Traditional glucose monitoring for children has always involved clinical touchpoints — regular appointments, prescription renewals, and device training sessions managed by endocrinologists or pediatricians. App-based CGM technology doesn't eliminate those relationships, but it does shift some of the monitoring responsibility back to families and caregivers in ways that can be genuinely empowering.
Real-time data shared between a child's device and a parent's smartphone means that a caregiver at work can see a glucose alert at the same moment their child is in a classroom across town. Remote monitoring capabilities built into apps like Dexcom's platform allow multiple followers — parents, grandparents, school nurses, and coaches — to receive alerts simultaneously. This kind of distributed oversight was simply not possible with older monitoring methods and represents a meaningful quality-of-life improvement for families managing pediatric metabolic health.
Beyond diagnosed conditions, the broader availability of CGM technology for children also opens up conversations about metabolic wellness more generally. Researchers and clinicians are increasingly interested in how glucose variability affects energy levels, cognitive performance, mood, and sleep in young people — even those without a formal diabetes diagnosis. App-based tracking makes it feasible, for the first time, to gather this kind of longitudinal data outside of research settings.
Key Considerations for Schools, Health Care Teams, and Benefits Leaders
While the technology is exciting, widespread adoption of OTC CGM devices for children introduces real-world complexities that institutions need to prepare for. Schools, health care teams, and employee benefits administrators are among the stakeholders who will need to adapt policies and practices in response.
Device Access and Equity
OTC clearance does not automatically mean affordable or universally accessible. CGM sensors carry ongoing costs — typically monthly — that can be prohibitive for lower-income families even without a prescription barrier. Benefits leaders at employers who provide family health coverage should examine whether OTC CGM devices are covered under existing health savings account (HSA) or flexible spending account (FSA) rules, and whether plan designs can be updated to support pediatric CGM access for dependents.
Caregiver Oversight and School Policies
Schools will need updated protocols that reflect the reality of students wearing continuous glucose monitors throughout the school day. This includes staff training on how to respond to alerts, guidance on whether school nurses should be added as app followers, and policies around students carrying connected smartphones to receive real-time data. Without thoughtful planning, well-intentioned technology can create confusion or liability gaps in school health programs.
Integration With Clinical Care
Health care providers should be prepared for patients and families arriving at appointments with weeks or months of continuous glucose data already collected via an OTC device. This is an opportunity — CGM data can dramatically enrich clinical conversations — but only if clinicians are equipped to interpret and act on app-generated reports. Pediatric practices may need to invest in staff education and workflow adjustments to make the most of this data.
The Road Ahead for Pediatric Glucose Technology
The FDA's clearance of Dexcom Stelo for children is unlikely to be an isolated development. As CGM technology continues to miniaturize and costs come down, more manufacturers will seek OTC clearance for pediatric populations. Integration with school health information systems, electronic health records, and insurance platforms is a logical next step that will require cross-sector collaboration between technology companies, health systems, and policymakers.
For now, the most important thing families, schools, and health care teams can do is stay informed, ask questions about coverage and clinical integration, and begin developing the policies and protocols that will allow this technology to benefit children safely and equitably. Glucose tracking for children has entered a new era — and the institutions that support children's health need to be ready to meet it.